<DOC>
	<DOC>NCT00364988</DOC>
	<brief_summary>Peroxisomal proliferator-activated receptor agonist pioglitazone and rosiglitazone are currently used in the treatment of type 2 diabetes, as efficient insulin sensitizers alone or in combination with insulin.angiotensin II receptor antagonist losartan reduced the levels of proteinuria.Whether Combination therapy with pioglitazone and losartan provides additional renoprotection in subjects with type 2 diabetic nephropathy,it's worth researching.</brief_summary>
	<brief_title>Pioglitazone and Losartan Provides Additional Renoprotection</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>Fasting plasma glucose (FPG) level of 3.39.0mmol/L 2h plasma glucose level of 7.513 mmol/L serum creatinine values between 190 and 660umol/L Two occasions of a ratio of urinary albumin to urinary creatinine≥300 or 24 hours urinary protein concentration is ＞150mg Informed consent Type1 diabetes or nondiabetic renal disease abnormal liver function heart dysfunction</criteria>
	<gender>All</gender>
	<minimum_age>32 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>pioglitazone</keyword>
	<keyword>losartan</keyword>
	<keyword>proteinuria</keyword>
	<keyword>end stage renal disease (ESRD)</keyword>
</DOC>